This company has been marked as potentially delisted and may not be actively trading. Edge Therapeutics (EDGE) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock EDGE vs. RYTM, PBH, PTCT, ZLAB, RNA, RARE, PRGO, AKRO, OGN, and CRNXShould you be buying Edge Therapeutics stock or one of its competitors? The main competitors of Edge Therapeutics include Rhythm Pharmaceuticals (RYTM), Prestige Consumer Healthcare (PBH), PTC Therapeutics (PTCT), Zai Lab (ZLAB), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Perrigo (PRGO), Akero Therapeutics (AKRO), Organon & Co. (OGN), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "medical" sector. Edge Therapeutics vs. Rhythm Pharmaceuticals Prestige Consumer Healthcare PTC Therapeutics Zai Lab Avidity Biosciences Ultragenyx Pharmaceutical Perrigo Akero Therapeutics Organon & Co. Crinetics Pharmaceuticals Edge Therapeutics (NASDAQ:EDGE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking. Which has more risk & volatility, EDGE or RYTM? Edge Therapeutics has a beta of 3.65, indicating that its share price is 265% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.32, indicating that its share price is 132% more volatile than the S&P 500. Do insiders and institutionals hold more shares of EDGE or RYTM? 28.0% of Edge Therapeutics shares are owned by institutional investors. 37.1% of Edge Therapeutics shares are owned by insiders. Comparatively, 5.6% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media refer more to EDGE or RYTM? In the previous week, Rhythm Pharmaceuticals had 16 more articles in the media than Edge Therapeutics. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 1 mentions for Edge Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 1.07 beat Edge Therapeutics' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edge Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend EDGE or RYTM? Rhythm Pharmaceuticals has a consensus price target of $74.92, indicating a potential upside of 13.68%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Edge Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edge Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is EDGE or RYTM more profitable? Edge Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Edge Therapeutics' return on equity of -81.29% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Edge TherapeuticsN/A -81.29% -56.92% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% Which has preferable valuation and earnings, EDGE or RYTM? Edge Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdge TherapeuticsN/AN/A-$40.86MN/AN/ARhythm Pharmaceuticals$130.13M32.02-$184.68M-$4.35-15.15 Does the MarketBeat Community prefer EDGE or RYTM? Rhythm Pharmaceuticals received 132 more outperform votes than Edge Therapeutics when rated by MarketBeat users. Likewise, 68.06% of users gave Rhythm Pharmaceuticals an outperform vote while only 66.79% of users gave Edge Therapeutics an outperform vote. CompanyUnderperformOutperformEdge TherapeuticsOutperform Votes17766.79% Underperform Votes8833.21% Rhythm PharmaceuticalsOutperform Votes30968.06% Underperform Votes14531.94% SummaryRhythm Pharmaceuticals beats Edge Therapeutics on 8 of the 15 factors compared between the two stocks. Get Edge Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDGE vs. The Competition Export to ExcelMetricEdge TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.17B$6.83B$5.54B$8.03BDividend YieldN/A2.95%5.09%4.22%P/E RatioN/A7.4722.7118.78Price / SalesN/A261.15407.35107.90Price / CashN/A65.8538.1834.62Price / Book38.926.616.804.34Net Income-$40.86M$143.37M$3.22B$247.93M Edge Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDGEEdge TherapeuticsN/A$36.98+0.5%N/A+919.1%$1.17BN/A0.00N/ARYTMRhythm Pharmaceuticals3.7761 of 5 stars$62.68+4.7%$74.92+19.5%+54.0%$3.96B$130.13M-14.47140Upcoming EarningsInsider TradePositive NewsPBHPrestige Consumer Healthcare3.9602 of 5 stars$79.92+0.2%$93.33+16.8%+16.0%$3.96B$1.12B18.72540Upcoming EarningsAnalyst UpgradePTCTPTC Therapeutics3.9769 of 5 stars$49.47-1.0%$63.92+29.2%+45.0%$3.90B$806.78M-8.321,410Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsZLABZai Lab2.1706 of 5 stars$33.73+0.3%$47.37+40.4%+95.9%$3.70B$398.99M-12.171,950Upcoming EarningsPositive NewsRNAAvidity Biosciences2.6957 of 5 stars$29.93-2.4%$66.69+122.8%+26.7%$3.60B$10.90M-10.39190Upcoming EarningsPositive NewsRAREUltragenyx Pharmaceutical4.3586 of 5 stars$37.63+0.9%$92.79+146.6%-10.0%$3.53B$560.23M-5.941,310Upcoming EarningsShort Interest ↑Positive NewsPRGOPerrigo4.8622 of 5 stars$24.94+0.8%$33.00+32.3%-23.1%$3.40B$4.37B-21.328,900Upcoming EarningsDividend AnnouncementShort Interest ↑Positive NewsAKROAkero Therapeutics3.7931 of 5 stars$41.11+3.8%$76.29+85.6%+125.6%$3.28BN/A-11.0030Upcoming EarningsNews CoveragePositive NewsOGNOrganon & Co.4.7684 of 5 stars$11.94+3.9%$20.60+72.6%-49.9%$3.08B$6.40B3.5810,000Earnings ReportAnalyst DowngradeOptions VolumeNews CoverageCRNXCrinetics Pharmaceuticals3.6572 of 5 stars$32.33-0.1%$73.00+125.8%-25.6%$3.01B$1.04M-8.67210Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Rhythm Pharmaceuticals Competitors Prestige Consumer Healthcare Competitors PTC Therapeutics Competitors Zai Lab Competitors Avidity Biosciences Competitors Ultragenyx Pharmaceutical Competitors Perrigo Competitors Akero Therapeutics Competitors Organon & Co. Competitors Crinetics Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDGE) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edge Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EDGE Stock Free EDGE Stock Alerts